Current Report Filing (8-k)
02 February 2023 - 12:46AM
Edgar (US Regulatory)
0001760903
false
0001760903
2023-02-01
2023-02-01
0001760903
us-gaap:CommonStockMember
2023-02-01
2023-02-01
0001760903
JUPW:WarrantsEachExercisableForOneShareOfCommonStockAt8.50PerShareMember
2023-02-01
2023-02-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C., 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 1, 2023
JUPITER
WELLNESS, INC.
(Exact
name of registrant as specified in charter)
Delaware |
|
001-39569 |
|
83-2455880 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
1061
E. Indiantown Rd., Ste. 110, Jupiter, FL 33477
(Address
of principal executive offices) (Zip Code)
(561)
244-7100
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
JUPW |
|
The
Nasdaq Stock Market LLC
(The
Nasdaq Capital Market) |
|
|
|
|
|
Warrants,
each exercisable for one share of Common Stock at $8.50 per share |
|
JUPWW |
|
The
Nasdaq Stock Market LLC
(The
Nasdaq Capital Market) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
On
February 1, 2023, Jupiter Wellness, Inc. (the “Company”) appointed Dr. Hector Alila as an additional director .
Dr.
Hector Alila, Director served as one of our directors from February 2019 to December 2022. Dr. Alila brings 30 years of demonstrated
scientific experience in product development and successful management leadership in biopharmaceutical industry. He is the Founding
President and Chief Executive Officer of Esperance Pharmaceutical Inc., a clinical stage biopharmaceutical company that has
successfully developed novel targeted cancer therapeutics currently in clinical development. Dr. Alila founded Esperance
Pharmaceutical, Inc. in 2006. Prior to Esperance, Dr. Alila served as Senior Vice President of Drug Development at Protalex, Inc.,
where he led the development of a drug currently in clinical trials for treatment of autoimmune diseases. He was previously Vice
President of Product Development at Cell Pathways, Inc., where he was responsible for the development cancer drugs, and a director
of Biology/pharmacology at GeneMedicine, Inc., where he led product development of gene medicines. He also held several research,
product development and management positions at SmithKline Beecham Pharmaceuticals. He obtained his Ph.D. in physiology and
immunology from Cornell University.
Item
7.01. Regulation FD Disclosure
On
February 1, 2023, Jupiter Wellness, Inc. (the “Company”) issued a press release. A copy of the press release is furnished
hereto as Exhibit 99.1 and incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
February 1, 2023
|
JUPITER
WELLNESS, INC. |
|
|
|
By: |
/s/
Brian John |
|
|
Brian
John |
|
|
Chief
Executive Officer |
Jupiter Wellness (NASDAQ:JUPW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jupiter Wellness (NASDAQ:JUPW)
Historical Stock Chart
From Jul 2023 to Jul 2024